Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.

Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.

Finan B, Ma T, Ottaway N, Müller TD, Habegger KM, Heppner KM, Kirchner H, Holland J, Hembree J, Raver C, Lockie SH, Smiley DL, Gelfanov V, Yang B, Hofmann S, Bruemmer D, Drucker DJ, Pfluger PT, Perez-Tilve D, Gidda J, Vignati L, Zhang L, Hauptman JB, Lau M, Brecheisen M, Uhles S, Riboulet W, Hainaut E, Sebokova E, Conde-Knape K, Konkar A, DiMarchi RD, Tschöp MH.

Sci Transl Med. 2013 Oct 30;5(209):209ra151. doi: 10.1126/scitranslmed.3007218.

2.

Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.

Maida A, Hansotia T, Longuet C, Seino Y, Drucker DJ.

Gastroenterology. 2009 Dec;137(6):2146-57. doi: 10.1053/j.gastro.2009.09.004. Epub 2009 Sep 17.

PMID:
19766644
3.

Incretin hormones and the satiation signal.

Holst JJ.

Int J Obes (Lond). 2013 Sep;37(9):1161-8. doi: 10.1038/ijo.2012.208. Epub 2013 Jan 8. Review.

4.

Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice.

Irwin N, Hunter K, Montgomery IA, Flatt PR.

Diabetes Obes Metab. 2013 Jul;15(7):650-9. doi: 10.1111/dom.12079. Epub 2013 Feb 26.

PMID:
23388064
5.

Metabolic effects of sustained activation of the GLP-1 receptor alone and in combination with background GIP receptor antagonism in high fat-fed mice.

Irwin N, McClean PL, Hunter K, Flatt PR.

Diabetes Obes Metab. 2009 Jun;11(6):603-10. doi: 10.1111/j.1463-1326.2009.01036.x. Epub 2009 Apr 13.

PMID:
19515180
6.
7.

GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.

Hansotia T, Drucker DJ.

Regul Pept. 2005 Jun 15;128(2):125-34. Review.

PMID:
15780432
8.

Discovery of dual-action membrane-anchored modulators of incretin receptors.

Fortin JP, Chinnapen D, Beinborn M, Lencer W, Kopin AS.

PLoS One. 2011;6(9):e24693. doi: 10.1371/journal.pone.0024693. Epub 2011 Sep 14.

9.

Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.

Neumiller JJ.

J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S16-29. doi: 10.1331/JAPhA.2009.09078. Review.

PMID:
19801361
12.

The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: incretins: concept and physiological functions.

Girard J.

Diabetes Metab. 2008 Dec;34(6 Pt 1):550-9. doi: 10.1016/j.diabet.2008.09.001. Epub 2008 Nov 25. Review.

PMID:
19036624
14.

Actions of incretin metabolites on locomotor activity, cognitive function and in vivo hippocampal synaptic plasticity in high fat fed mice.

Porter D, Faivre E, Flatt PR, Hölscher C, Gault VA.

Peptides. 2012 May;35(1):1-8. doi: 10.1016/j.peptides.2012.03.014. Epub 2012 Mar 24.

PMID:
22465882
15.

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.

Finan B, Yang B, Ottaway N, Smiley DL, Ma T, Clemmensen C, Chabenne J, Zhang L, Habegger KM, Fischer K, Campbell JE, Sandoval D, Seeley RJ, Bleicher K, Uhles S, Riboulet W, Funk J, Hertel C, Belli S, Sebokova E, Conde-Knape K, Konkar A, Drucker DJ, Gelfanov V, Pfluger PT, Müller TD, Perez-Tilve D, DiMarchi RD, Tschöp MH.

Nat Med. 2015 Jan;21(1):27-36. doi: 10.1038/nm.3761. Epub 2014 Dec 8.

PMID:
25485909
16.

Incretin hormone mimetics and analogues in diabetes therapeutics.

Green BD, Flatt PR.

Best Pract Res Clin Endocrinol Metab. 2007 Dec;21(4):497-516. Review.

PMID:
18054732
17.

Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents.

Day JW, Gelfanov V, Smiley D, Carrington PE, Eiermann G, Chicchi G, Erion MD, Gidda J, Thornberry NA, Tschöp MH, Marsh DJ, SinhaRoy R, DiMarchi R, Pocai A.

Biopolymers. 2012;98(5):443-50. doi: 10.1002/bip.22072.

PMID:
23203689
18.

Incretins yesterday, pleiotropic gastrointestinal hormones today:glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).

Kiec-Klimczak ME, Pach DM, Pogwizd ME, Hubalewska-Dydejczyk AB.

Recent Pat Endocr Metab Immune Drug Discov. 2011 Sep;5(3):176-82. Review.

PMID:
21913887
19.

GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes.

Mentis N, Vardarli I, Köthe LD, Holst JJ, Deacon CF, Theodorakis M, Meier JJ, Nauck MA.

Diabetes. 2011 Apr;60(4):1270-6. doi: 10.2337/db10-1332. Epub 2011 Feb 17.

20.

Supplemental Content

Support Center